Hi Guys, sorry to go off in a tangent. Its filler time.
Globe says Lorus pancreatic cancer study moves forward
Lorus Therapeutics Inc
LOR
Shares issued 140,247,667
Oct 9 2001 close $1.010
Wednesday Oct 10 2001
In the News
The Globe and Mail reports in its Wednesday, Oct. 10, edition that an unnamed
industry analyst says while he is pleased to see the marketing agreement between
Lorus Therapeutics and F.H. Faulding & Co., "my concern is that they're spending so
much time on melanoma in Mexico when the potential for Virulizin to treat pancreatic
cancer is enormous." The Globe's Leonard Zehr writes that Lorus is preparing to begin
a $12-million (Canadian) late-stage test of Virulizin in patients with pancreatic cancer,
which represents an annual $400-million (U.S.) market. It also is holding talks with
pharmaceutical companies to distribute the drug, which could be on the market in
2004.
(c) Copyright 2001 Canjex Publishing Ltd. canada-stockwatch.com
How do you guys interpret the phrase "potential for Virulizin to treat pancreatic cancer is enormous"?
1. the drug's potential is to treat pancreatic cancer positively is enormous?
2. the potential to grab market share of an annual $400 million US market is enormous?
If the latter, I wonder what this unnamed industry analyst may refer to a market that is $5 to $12 Billion in size? Can't be enormous. Gotta be "bigger than huge", gigantic, colossal, .... Help me out.
Also note that in less than a year LOR has about doubled its number of shares outstanding. DMX is diluting somewhat at this time, but at a much much better rate than LOR.
BTW, another Trivia to show how under valued DMX is:
QLT appears to be on course to make $250mm revenue this fiscal year. Currently YTD revenues are about $250mm. They have a complicated (to me) revenue and net income sharing agreement with Novartis. I think projected net income will come in at about $0.63 per share this fiscal year. Or about 60 times P/E!! I'm still trying to figure out how large their market is and its expected growth rate. Unlike OA which doesn't go away (unless a cure happens), QLT's Visudyne will "need a fresh supply" of new patients every year to treat. That is, if I understand correctly that Visudyne is a "cure." QLT's real reason for existance is its photo activate drug delivery system, like DMX's non-systematic transdermal drug delivery system. |
